IGF-I, insulin and prostate cancer

被引：21

作者：

Balarini Lima, Giovanna A. ^{[1
]}

Correa, Livia L.

Gabrich, Rafael ^{[2
]}

de Miranda, Luiz Carlos D. ^{[2
]}

Gadelha, Monica R. ^{[3
]}

机构：

[1] Univ Fed Rio de Janeiro, HUCFF, Ilha Fundao, Serv Endocrinol, BR-21941913 Rio de Janeiro, Brazil

[2] Univ Fed Rio de Janeiro, HUCFF, Serv Urol, BR-21941913 Rio de Janeiro, Brazil

[3] Inst Estadual Diabet & Endocrinol Luiz Capriglion, Serv Endocrinol, Rio De Janeiro, Brazil

来源：

ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA | 2009年 / 53卷 / 08期

关键词：

Insulin; IGF-I; prostate; cancer; GROWTH-FACTOR-I; FACTOR-BINDING PROTEIN-3; DIABETES-MELLITUS; COLORECTAL-CANCER; FACTOR (IGF)-I; BREAST-CANCER; PLASMA-LEVELS; RISK; MEN; METAANALYSIS;

D O I：

10.1590/S0004-27302009000800010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer is the second most frequent malignancy diagnosed in adult men. Androgens are considered the primary growth factors for prostate normal and cancer cells. However, other non-androgenic growth factors are involved in the growth regulation of prostate cancer cells. The association between IGF-I and prostate cancer risk is well established. However, there is no evidence that the measurement of IGF-I enhances the specificity of prostate cancer detection beyond that achievable by serum prostate-specific antigen (PSA) levels. Until now, there is no consensus on the possible association between IGFBP-3 and prostate cancer risk. Although not well established, it seems that high insulin levels are particularly associated with risk of aggressive prostatic tumours. This review describes the physiopathological basis, epidemiological evidence, and animal models that support the association of the IGFs family and insulin with prostate cancer. It also describes the potential therapies targeting these growth factors that, in the future, can be used to treat patients with prostate cancer. Arq Bras Endocrinol Metalb. 2009;53(8):969-75

引用

页码：969 / 975

页数：7

共 63 条

[1] Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3 [J].